Clareo Health | Immunotherapy Following Reduced Intensity Conditioning and Allogeneic Stem Cell Transplant for Poor Risk CD30+ Hodgkin Lymphoma Patients
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
New York Medical College
With
St. Baldrick's Foundation
Age
0–45
Sex
ALL
Healthy volunteers
Accepted
You may be eligible if
45 years of age or less.
Patients with Hodgkin Lymphoma with either of the following:
• Primary induction failure (failure to achieve initial CR) and/or primary refractory disease OR First, Second or Third relapse AND History of prior ablative auto HSCT or ineligible for an ablative auto HSCT or ≥25% residual disease after at least two reinduction chemotherapy cycles AND HLA matched family donor (6/6 or 5/6) or matched unrelated adult donor (MUD) (8/8) or matched umbilical cord blood unit (≥5/6) with prethaw cell dose of at least 3 x 107/kg TNC.
off other investigational therapy for one month prior to entry in this study.
adequate organ function
You may not be if
Patients with HD with 4th or greater CR, PR, and/or SD are ineligible.
Patients with rapidly progressive disease (PD) unresponsive to reinduction chemo, radio, or immunotherapy are ineligible.
Patients who don't have an eligible donor are ineligible.
